US2011003747A1PendingUtilityA1

Use of nrf2 inducers to treat epidermolysis bullosa simplex and related diseases

59
Individually held — no corporate assignee on recordPriority: Jul 20, 2007Filed: Jul 17, 2008Published: Jan 6, 2011
Est. expiryJul 20, 2027(~0.9 yrs left)· nominal 20-yr term from priority
Inventors:Pierre A. ColoumbeMichelle L. Kerns
A61K 31/497A61K 38/1825A61K 31/00A61K 31/275A61K 31/26A61P 17/00A61K 9/0014
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to methods and compositions for the prevention and treatment of keratin-based skin diseases. In particular, the application describes compositions and methods of treating a patient suffering from skin blistering comprising the use of phase II enzyme inducers.

Claims

exact text as granted — not AI-modified
1 . A method to ameliorate the mechanical resilience of skin in a patient in need thereof comprising administering to the patient a composition comprising a therapeutically effective amount of an Nrf2 inducer. 
     
     
         2 . The method of  claim 1 , wherein the patient suffers from skin blistering. 
     
     
         3 . The method of  claim 1 , wherein the Nrf2 inducer is a phase II enzyme inducer. 
     
     
         4 . The method of  claim 3 , wherein the phase II inducer is an isothiocyanate. 
     
     
         5 . The method of  claim 4 , wherein the phase IT enzyme inducer is sulforaphane. 
     
     
         6 . The method of  claim 4 , wherein the phase II enzyme inducer is a sulforaphane synthetic analogue. 
     
     
         7 . (canceled) 
     
     
         8 . The method of  claim 1 , wherein the Nrf2 inducer is keratinocyte growth factor. 
     
     
         9 - 11 . (canceled) 
     
     
         12 . The method of  claim 1 , wherein the composition comprising the Nrf2 inducer is topically administered to the patient. 
     
     
         13 - 15 . (canceled) 
     
     
         16 . The method of  claim 1 , wherein the patient is a mammal. 
     
     
         17 . The method of  claim 16 , wherein the mammal is a human. 
     
     
         18 . A method for treating or preventing skin blistering in a patient comprising administering to the patient a composition comprising a therapeutically effective amount of an Nrf2 inducer. 
     
     
         19 . The method of  claim 18 , wherein the patient suffers from Epidermolysis bullosa simplex. 
     
     
         20 . The method of  claim 18 , wherein the patient suffers from Epidermolysis bullosa simplex-Weber-Cockayne type, Epidermolysis bullosa simplex-Koebner type, Epidermolysis bullosa simplex with mottled pigmentation, Epidermolysis bullosa simplex-Dowling-Meara type, or Epidermolysis bullosa simplex with muscular dystrophy. 
     
     
         21 . The method of  claim 20 , wherein the Epidermolysis bullosa simplex is caused by a mutation at the K14 locus. 
     
     
         22 . The method of  claim 18 , wherein the Nrf2 inducer is a phase II enzyme inducer. 
     
     
         23 - 36 . (canceled) 
     
     
         37 . A method for treating or preventing a keratin-based skin disease in a patient comprising administering to the patient a composition comprising a therapeutically effective amount of an Nrf2 inducer. 
     
     
         38 . The method of  claim 37 , wherein the keratin-based skin disease is selected from the group consisting of epidermolytic hyperkeratosis, ichtyosis bullosa of Siemens, pachyonychia congenita, epidermolytic or non-epidermolytic palmoplantar keratoderma (diffuse or focal) steatocystoma multiplex, Nacgeli-Franceschetti-Jadassohn syndrome and dermatopathia pigmentosa reticularis. 
     
     
         39 - 54 . (canceled) 
     
     
         55 . A composition for topical application to the skin comprising a therapeutically effective amount of an Nrf2 inducer and a carrier that allows the Nrf2 inducer to reach basal keratinocytes in the epidermis. 
     
     
         56 . (canceled) 
     
     
         57 . The composition of  claim 55 , wherein the Nrf2 inducer is a phase II enzyme inducer. 
     
     
         58 - 67 . (canceled)

Join the waitlist — get patent alerts

Track US2011003747A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.